News | November 20, 2006

Stem Cell Company Moves Closer to U.S. Cardiac Market

In its third quarter financial report, San Diego-based Cytori said it has moved significantly closer to initiating its cardiovascular clinical trials," said Christopher J. Calhoun, chief executive officer of Cytori Therapeutics. The company is developing adipose stem cells in cardiovascular disease and for use in reconstructive surgery.

"The first trial is expected to start before year end in patients suffering from chronic ischemia, a severe form of coronary artery disease, and the heart attack trial is expected to begin in early 2007.

Cytori received U.S. 510(K) regulatory clearance recently on the Celution Cell Concentration System as a cell saver device by the FDA's Center for Devices and Radiological Health (CDRH)

For more information visit www.cytoritx.com

Related Content

Figure 1: A computed tomography angiography (CTA) study performed for transcatheter aortic valve replacement planning.  Interventional imagers created and interpret these images as part of the heart team.

Figure 1: A computed tomography angiography (CTA) study performed for transcatheter aortic valve replacement planning. The aortic valve is trileaflet with significant calcification (A). Annular measurements are performed to determine valve sizing (B). Coronary artery height is measured to predict the risk of coronary artery obstruction (C).  

Feature | Structural Heart | April 24, 2019 | Nadeen N. Faza, M.D., Dee Dee Wang, M.D., Joao Cavalcante, M.D., Andrew D. Choi, M.D., Jeffrey B. Geske, M.D., and Stephen H. Little, M.D.
Recent months have signaled a new and exciting era in the dynamic world of...
All major vendors offering advanced visualization software now offer structural heart planning. This is an example of GE Healthcare's Valve Assist software being used to determine the best location of a transseptal puncture to deliver a left atrial appendage (LAA) occluder.

All major vendors offering advanced visualization software now offer structural heart planning. This is an example of GE Healthcare's Valve Assist software being used to determine the best location of a transseptal puncture to deliver a left atrial appendage (LAA) occluder. 

Feature | Structural Heart | March 28, 2019 | Jeff Zagoudis
Structural heart interventions represent one of the fastest growing segments of cardiology, as the number of devices
A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation. Abbott Mitraclip device.

A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation.

News | Structural Heart | May 11, 2018
May 11, 2018 — The post-approval study evaluating the safety and efficacy of MitraClip in a real-world, commercial se
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart | January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Videos | Structural Heart | November 09, 2016
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart | August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
Overlay Init